Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;46(7):1423-1428.
doi: 10.1007/s40618-022-02001-3. Epub 2023 Jan 18.

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort

D Caldeira  1   2   3 , M Alves  4   5   6 , J J Ferreira  4   5 , F J Pinto  7   8
Affiliations

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort

D Caldeira et al. J Endocrinol Invest. 2023 Jul.

Abstract

Purpose: Aspirin use among patients with diabetes in primary prevention is still a matter of debate. We aimed to evaluate the potential cardiovascular risk benefit of aspirin in primary prevention, using data from a contemporary cohort.

Methods: Retrospective analysis of the VITAL cohort with > 20,000 individuals at primary prevention who were followed for a median of 5.3 years. The population was evaluated according to the baseline diabetes status, and then aspirin use was evaluated among diabetic patients. Cox regression models were used to estimate the risks of mortality and cardiovascular outcomes. The estimates were reported using adjusted hazard ratio (HR) and 95% confidence intervals (95%CI).

Results: Diabetic patients (n = 3549; 13.7%) showed to increase the risk of all-cause mortality (HR 1.61, 95%CI 1.33-1.94), and major adverse cardiovascular events (MACE) (HR 1.36 95%CI 1.11-1.68) than non-diabetic population. Diabetic patients taking aspirin were older, more frequently man, hypertensive, current users of statins, and current smokers compared with diabetic patients who did not use aspirin at baseline. There was no difference between diabetic aspirin users and non-users regarding all-cause mortality (HR 0.80, 95%CI 0.59, 1.10), MACE (HR 0.92, 95%CI 0.64, 1.33), coronary heart disease (HR 0.98, 95%CI 0.67, 1.43), or stroke (HR 0.87, 95%CI 0.48, 1.58).

Conclusions: The VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.

Keywords: Aspirin; Cardiovascular disease; Diabetes; Primary prevention.

PubMed Disclaimer

Conflict of interest statement

DC has participated in educational meetings and/or attended a conferences or symposia (including travel, accommodation and/or hospitality) with Bial, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, Ferrer, Pfizer, Novartis and Roche. JJF is a consultant for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck Serono, and Merz and received grants from GlaxoSmithKline, Grunenthal, Teva, and Fundação MSD. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim and Daiichi Sankyo. The remaining authors have nothing to declare.

Figures

Fig. 1
Fig. 1
Flowchart showing the patients according to baseline diabetes status and aspirin use in diabetics
Fig. 2
Fig. 2
Plot showing the estimates (unadjusted and adjusted) in hazard ratios for diabetes (left side) and for aspirin in diabetic patients (right side). Adjusted estimates accounted for age, sex, body mass index, smoking status, parental history of myocardial infarction, hypertension, statins use. CHD: Coronary heart disease; CI Confidence interval, CV Cardiovascular, MACE Major adverse cardiovascular events, MI Myocardia infarction
Fig. 3
Fig. 3
Cumulative hazard plot showing the increased risk of Major Adverse Cardiovascular Events (MACE) of diabetic patients compared to non-diabetic individuals
See this image and copyright information in PMC

References

    1. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9. - DOI - PubMed
    1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78. doi: 10.1136/bmj.38678.389583.7C. - DOI - PMC - PubMed
    1. O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–775. doi: 10.1016/S0140-6736(16)30506-2. - DOI - PubMed
    1. Kannel WB, McGee DL. Diabetes and cardiovascular disease the framingham study. J American Med Associat. 1979;241(19):2035–2038. doi: 10.1001/jama.1979.03290450033020. - DOI - PubMed
    1. ASCEND Study Collaborative Group. Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–1539. doi: 10.1056/NEJMoa1804988. - DOI - PubMed